Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Thanks for that Safy, I made a comment earlier about it not being a guarantee for £75m and it being a maximum amount but was promptly told I was a knob!!!
Pharmaco nutrition is not pharma and I don't doubt that pharma is a full time job and couldn't be done on the side.
I thought the point of these boards was to share experience, and public sector procurement is mine.
Ha, good find!! I have a 9-5 and a side hustle. Winning contracts is my 9-5.
I haven't bid for covid and there could be many exemptions that could be applied to these contracts given the situation.
I tried to give a balanced argument, and winning a contract is great news, I am sharing my experience of public sector procurement.
I also said I could be completely wrong and obviously don't know the details of the contract.
Hi all,
I've seen a lot being made of the £75m contract.
My job is to win public sector contracts through tenders. The field I work in is health and social care and typically a tender and contract value will be for the absolute maximum, and not be a guarantee. I have not yet seen a contract value be reached, and normally it is substantially less than that advertised.
If this was a contract I was bidding for/winning i would treat that number with caution.
These are exceptional times and I could easily be wrong and clearly I don't have sight of the contract, but I wanted to share my experiences of public sector procurement.
I hope this isn't taken as a deramp, and winning a tender/contract is clearly hugely positive, but I would be cautious about that contract value.
Take care all
Hemogenyx Pharmaceuticals plc
(the “Company”)
Agreement for the Development of New Treatments for Autoimmune Diseases
Hemogenyx Pharmaceuticals plc is pleased to announce that it has signed a Biological Investigation and Material Supply Agreement (“Agreement”) with a leading global pharmaceutical company (“GlobalCo”) engaged in the research, development, manufacture, and marketing of pharmaceutical products.
Under the Agreement, GlobalCo will supply the Company with certain biological materials and related confidential information in order for the Company to perform research and development activities aimed at the discovery and validation of novel materials (“Materials”) to be used for the treatment of systemic lupus erythematosus (“Lupus”) and possibly other autoimmune diseases.
This Agreement will fully complement the Company’s own development work currently being undertaken. The Agreement stipulates certain confidential provisions, including, at this stage, the pharmaceutical company’s identity. GlobalCo is the same organization with which the Company is collaborating to develop its CDX antibody product candidate and with which it also has a research agreement for the development of the Company’s humanized mice.
Under the Agreement, the Company will grant GlobalCo a research license for anything jointly developed under the Agreement, as well as an option for an exclusive worldwide license to commercially exploit jointly developed Materials. If the option is not exercised by GlobalCo, the Company will have an option to license the jointly developed Materials itself.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: “This is a very encouraging agreement that provides additional support for our own plans for the development of novel treatments for Lupus and other autoimmune diseases. It fully complements the work that we are already undertaking with our own resources. This close collaboration offers the potential for ongoing value-adding licensing arrangements with a major pharmaceutical company with the benefit of their global reach and large-scale resources. It is gratifying to be able to report our close and developing relationship with GlobalCo.”
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals plc is a publicly-traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located at its state-of-the-art research facility in New York City and a Belgian subsidiary, Hemogenyx-Cell SPRL, located in Liège.
Hemogenyx Pharmaceuticals plc is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bri
The way I read this is that they need temp support to get through this busy period.
I see this as very positive and I would imagine this ties in to a strategic approach. Senior role gets the targetted big deals started, junior comes in to provide support and to either directly target second tier targets, or assist the senior with the added workload resulting from multiple contracts being negotiated.
D-Gee, spot on. The fact this is still rumbling on worries me greatly.
Yep, every time I see any RNS
Let's hope today is the start of what we all know can be achieved here. We've been patient the last few weeks and seen other shares rocket of off very little.
Surely now we can start to look at a substantially bigger and more realistic MC????
I think it is, but it's not the short term transformational news we wanted.
We now have a route to the consumer market and that will generate a lot of income.
Yes Medusa are new but they will publicise heavily and consumers don't need to be told or adviced about this, the demand is there we just needed the ability to get it to them and we now have it.
An anti-inflammatory syndrome or an inflammatory syndrome?
I work for a pharmaco nutrition company that specialises in anti-inflammatory products. There are big long term health problems with inflammation, but I don't know of any anti-inflammatory issues. But I'm not the scientist that creates them!!!